Clinical outcomes and predictive factors in oral corticosteroid-refractory active ulcerative colitis

Table 5 Comparison of clinical factors in one year outcomes of the two groups of active ulcerative colitis patients receiving intravenous corticosteroids after oral corticosteroid therapy failure

	Good responders1(n = 25)	Poor responders2(n = 29)	P-value univariate
Gender (M/F)	15/10 (60/40)	16/13 (55/45)	0.721
Age (yr)	35 (16-78)	39 (13-64)	0.445
Disease duration (mo)	30 (0-84)	29 (0-120)	0.325
≤ 24	14 (56)	20 (69)
> 24	11 (44)	9 (31)
First attack of UC	9 (36)	15 (51.7)	0.248
Disease extent			0.304
Proctitis	1 (4)	3 (10.3)
Left-sided colitis	6 (24)	11 (37.9)
Extensive colitis	18 (72)	15 (51.7)
Disease activity
Full Mayo score (< 9/≥ 9)	15/9 (62.5/37.5)	11/14 (44/56)	0.195
Partial Mayo score (< 6/≥ 6)	9/16 (36/64)	4/25 (13.8/86.2)	0.057
Initial prednisolone dose (mg)			0.785
≥ 30 and < 40	13 (52)	14 (48.3)
≥ 40	12 (48)	15 (51.7)
Duration of oral corticosteroid use (d)			0.337
≤ 14	17 (68)	16 (55.2)
> 14	8 (32)	13 (44.8)
Concomitant medications			0.771
Salicylates	19 (76)	23 (79.3)
Azathioprine	6 (24)	6 (20.7)
CRP (mg/dL)
≤ 8	16 (64%)	19 (65.5)	0.907
> 8	9 (36%)	10 (34.5)
ESR (mm/h)	34.1 (4-81)	46.3 (3-120)	0.171
Hemoglobin (mg/dL)
≤ 11	9 (36)	8 (27.6)	0.507
> 11	16 (64)	21 (72.4)
Albumin (mg/dL)	3.8 (2.7-4.7)	3.57 (2.3-5.0)	0.230

¹Good responders included patients with prolonged response that maintained complete remission or partial remission after corticosteroid therapy had finished;

²Poor responders included patients with steroid dependence and non-response. M/F: Male/female; UC: Ulcerative colitis; CRP: C-reactive protein; ESR: Erythrocyte sedimentation rate.